163 related articles for article (PubMed ID: 19164263)
21. Impacts of icodextrin on integrin-mediated wound healing of peritoneal mesothelial cells.
Matsumoto M; Tamura M; Miyamoto T; Furuno Y; Kabashima N; Serino R; Shibata T; Kanegae K; Takeuchi M; Abe H; Okazaki M; Otsuji Y
Life Sci; 2012 Jun; 90(23-24):917-23. PubMed ID: 22564410
[TBL] [Abstract][Full Text] [Related]
22. Comparison of icodextrin and glucose solutions for long dwell exchange in peritoneal dialysis: a meta-analysis of randomized controlled trials.
Qi H; Xu C; Yan H; Ma J
Perit Dial Int; 2011; 31(2):179-88. PubMed ID: 21119069
[TBL] [Abstract][Full Text] [Related]
23. The effect of icodextrin-based solutions on peritoneal transport in rats undergoing chronic peritoneal dialysis.
Pawlaczyk K; Garcia-Lopez E; Kuzlan-Pawlaczyk M; Heimbürger O; Bergström J; Breborowicz A; Lindholm B
Perit Dial Int; 2001; 21 Suppl 3():S359-61. PubMed ID: 11887855
[TBL] [Abstract][Full Text] [Related]
24. Diuretic-resistant congestive heart failure treated successfully with peritoneal ultrafiltration.
Próchnicka A; Krzesiński P; Hałas K; Dziuk M; Niemczyk S; Wańkowicz Z
Kardiol Pol; 2013; 71(4):393-5. PubMed ID: 23788345
[TBL] [Abstract][Full Text] [Related]
25. Comparison of icodextrin- and glucose-based peritoneal dialysis fluids in their acute and chronic effects on human peritoneal mesothelial cells.
Bender TO; Witowski J; Ksiazek K; Jörres A
Int J Artif Organs; 2007 Dec; 30(12):1075-82. PubMed ID: 18203069
[TBL] [Abstract][Full Text] [Related]
26. Use of new peritoneal dialysis solutions in children.
Canepa A; Verrina E; Perfumo F
Kidney Int Suppl; 2008 Apr; (108):S137-44. PubMed ID: 18379537
[TBL] [Abstract][Full Text] [Related]
27. Novel approaches to prescribing icodextrin.
Blake PG
Perit Dial Int; 2009; 29(4):412-4. PubMed ID: 19602606
[No Abstract] [Full Text] [Related]
28. Dialysis patient safety: safeguards to prevent iatrogenic hypoglycemia in patients receiving icodextrin.
Sloand JA
Am J Kidney Dis; 2012 Oct; 60(4):514-6. PubMed ID: 22835903
[No Abstract] [Full Text] [Related]
29. Icodextrin's effects on peritoneal transport.
Krediet RT; Ho-dac-Pannekeet MM; Imholz AL; Struijk DG
Perit Dial Int; 1997; 17(1):35-41. PubMed ID: 9068020
[TBL] [Abstract][Full Text] [Related]
30. Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritoneal dialysis patients.
Moriishi M; Kawanishi H; Tsuchiya S
Adv Perit Dial; 2006; 22():24-8. PubMed ID: 16983933
[TBL] [Abstract][Full Text] [Related]
31. The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients.
Gürsu EM; Ozdemir A; Yalinbas B; Gürsu RU; Canbakan M; Güven B; Atasoyu EM; Keskin AT; Elçi A; Baru Y
Clin Nephrol; 2006 Oct; 66(4):263-8. PubMed ID: 17063993
[TBL] [Abstract][Full Text] [Related]
32. Determination of alpha-amylase activity in serum and dialysate from patients using icodextrin-based peritoneal dialysis fluid.
Anderstam B; García-López E; Heimbürger O; Lindholm B
Perit Dial Int; 2003; 23(2):146-50. PubMed ID: 12713081
[TBL] [Abstract][Full Text] [Related]
33. Predictors of a favourable response to icodextrin in peritoneal dialysis patients with ultrafiltration failure.
Wiggins KJ; Rumpsfeld M; Blizzard S; Johnson DW
Nephrology (Carlton); 2005 Feb; 10(1):33-6. PubMed ID: 15705179
[TBL] [Abstract][Full Text] [Related]
34. Strategy for preventing peritoneal dialysis failure.
Cancarini G
Contrib Nephrol; 2001; (131):114-24. PubMed ID: 11125557
[No Abstract] [Full Text] [Related]
35. Peritoneal dialysis as a therapeutic approach in congestive heart failure resistant to pharmacological treatment: case report.
Próchnicka A; Olszowska A; Baczyński D; Zelichowski G; Lubas A; Wiśniewska M; Dziekiewicz M; Wańkowicz Z
Pol Arch Med Wewn; 2009 Dec; 119(12):834-7. PubMed ID: 20010472
[TBL] [Abstract][Full Text] [Related]
36. Icodextrin and peritoneal dialysis: advantages and new applications.
Dousdampanis P; Musso CG; Trigka K
Int Urol Nephrol; 2018 Mar; 50(3):495-500. PubMed ID: 28674854
[TBL] [Abstract][Full Text] [Related]
37. Effects of icodextrin on insulin resistance and adipocytokine profiles in patients on peritoneal dialysis.
Takeguchi F; Nakayama M; Nakao T
Ther Apher Dial; 2008 Jun; 12(3):243-9. PubMed ID: 18503703
[TBL] [Abstract][Full Text] [Related]
38. Sodium removal in peritoneal dialysis: the role of icodextrin and peritoneal dialysis modalities.
Fourtounas C; Hardalias A; Dousdampanis P; Papachristopoulos B; Savidaki E; Vlachojannis JG
Adv Perit Dial; 2008; 24():27-31. PubMed ID: 18985997
[TBL] [Abstract][Full Text] [Related]
39. Icodextrin reduces insulin resistance in non-diabetic patients undergoing automated peritoneal dialysis: results of a randomized controlled trial (STARCH).
de Moraes TP; Andreoli MC; Canziani ME; da Silva DR; Caramori JC; Ponce D; Cassi HV; de Andrade Bastos K; Rio DR; Pinto SW; Filho SR; de Campos LG; Olandoski M; Divino-Filho JC; Pecoits-Filho R
Nephrol Dial Transplant; 2015 Nov; 30(11):1905-11. PubMed ID: 26063787
[TBL] [Abstract][Full Text] [Related]
40. Newly Developed Neutralized pH Icodextrin Dialysis Fluid: Nonclinical Evaluation.
Yamaguchi N; Miyamoto K; Murata T; Ishikawa E; Horiuchi T
Artif Organs; 2016 Aug; 40(8):E158-66. PubMed ID: 27530675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
